Empowered by state-of-the-art technologies and advanced platforms in the field of antibody discovery and immunotherapy, Creative Biolabs now offers world-leading Chimeric Antigen Receptor Macrophage (CARMA) services for solid tumor treatment with academic or clinical purposes.
With the approvement of two CAR-T cell therapies in 2017, the CAR-T cell treatment has been a promising tool for the treatment of advanced hematologic malignancies. However, although a lot of CAR-T cell therapies are under preclinical evaluation, this approach has not been proved to be as successful in solid tumors. One of the limitations in solid tumor lies in the poor penetration of T cells into tumors. To address this need, talented scientists from Creative Biolabs turn to genetically engineered CARMA, also termed MOTO-CAR, aiming to improve the ability of CAR cells to attack solid tumors.
2. Introduction of Macrophage
Macrophage belongs to an innate immune cell and it is actively recruited into the tumor microenvironment by tumor-derived chemokines. Besides, there are reports saying macrophage represents up to 50% of the tumor mass. Therefore, these properties make it easier to penetrate tumor nodules, which has been challenging for adoptive T-cell techniques. Moreover, macrophage has the capacity to selectively destroy cancer cells via phagocytosis. In addition, macrophages exert multiple immune effector functions, participating in immune response, e.g. they are able to directly present antigens to T cells and stimulate an anti-tumor immune response when polarized towards the M1 phenotype. Given to the attractive features of macrophages, our approach is to use the macrophages isolated from the blood and genetically engineer them to express a CAR - which means now we tell them what to eat - to set them loose on the tumor to destroy the malignant cells.
3. One-stop CARMA Services
With the help of rich experience and scientific teams in CAR-T therapy, Creative Biolabs is confident to offer one-stop serves of CARMA including but not limited to:
Target Identification & Selection
We are not only capable of discovery potential targets in solid tumor cells but also good at developing suitable CARMA therapy targets with greater potency and lower toxicity.
High Affinity Antigen Binder Generation
Aided by our well-established antibody discovery platforms, we can obtain high affinity antibodies in various formats (such as scFv, Fab, VHH) with high specificity by conventional hybridoma technology, powerful phage display technology, and/or advanced native B cell sorting technology.
CAR Design and Virus Packaging
Customized CAR constructions are designed for each project. To get over the gene engineering hurdles when using macrophages in adoptive cell therapies, we developed a unique macrophage gene transfer approach. This novel strategy confers on our CARMA a desirable anti-tumor phenotype along with resistance to tumor-induced subversion that otherwise polarizes non-engineered macrophages to an immunosuppressive, pro-tumor phenotype.
d. In Vitro Assessments
Creative Biolabs can perform various in vitro assessments according to your requirements, which include CAR expression validation, CARMA function measurement, phagocytosis test against target cells, etc. For more details.
Preclinical Tests and Clinical Trials
We are expert in construction animal models for preclinical tests. Both efficacy and toxicity are well evaluated during this stage. Of note, we had several positive results saying the infusion of human CAR-macrophages into tumor-bearing mice leads to long-term tumor control and enhanced survival. In addition, clinical project management and execution are also on our list.
Over years in the field of immunotherapy, Creative Biolabs is more than happy to share our technologies, platforms, and experience to facilitate your projects and push the progress towards clinical trials. Please feel free to contact us for more details and our team will get back to you as soon as possible.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE